Arcutis Q1 product revenue $21.6M up 675% YoY; net loss narrows to $35.4M

Arcutis Biotherapeutics, Inc.

2024-Q1 EPS reported -$0.32 revenue$49,569,000

Q1 product revenue $21.6M ($15M cream, $6.5M foam) vs $2.8M in Q1 2023; 59% QoQ growth.
Net loss $35.4M ($0.32/sh) vs $80.1M ($1.31/sh) in Q1 2023; cash $404.5M at March 31.
PDUFA date July 7, 2024 for roflumilast cream 0.15% in atopic dermatitis (ages 6+).
Completed $172.5M public offering in February; licensing deal with Sato Pharma for Japan.
Appointed David Topper CFO effective April 10, 2024; sNDA for scalp/body psoriasis expected Q3 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $21.6 million.

Period: the quarter ended March 31, 2024
Revenue: $21.6 million
Result: reported results

Exact text from the filing

3027 Townsgate Road, Suite 300 Westlake Village, CA 91361 | arcutis.com First Quarter 2024 Summary Financial Results Product revenues for the quarter ended March 31, 2024 were $21.6 million compared to $2.8 million for the corresponding period in 2023. Revenues for the quarter were $15.0 million for ZORYVE (roflumilast) cream 0.3% and $6.5 million for ZORYVE

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-24-000078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.